Shigella mediated regulation of epithelial cell inflammasomes
志贺氏菌介导的上皮细胞炎症小体的调节
基本信息
- 批准号:10608342
- 负责人:
- 金额:$ 76.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-14 至 2028-03-31
- 项目状态:未结题
- 来源:
- 关键词:ActinsAcuteAntibiotic ResistanceBacteriaBindingBinding ProteinsCASP1 geneCASP4 geneCASP5 geneCaspaseCell DeathCell membraneCell physiologyCellsCessation of lifeCollaborationsColonComplexCytolysisCytosolDataDevelopmentDiarrheaEnvironmentEpithelial CellsEpitheliumFaceFutureGBP1 geneGastrointestinal tract structureGoalsGrowthHost DefenseHumanIL18 geneImmune responseInfectionInfection preventionInflammasomeInflammationInflammatoryInnate Immune ResponseInterferonsInterleukin-1 betaInterruptionInterventionInvadedIonsKnowledgeLearningLipid ALipopolysaccharidesMediatingModelingModificationMusN-terminalNeutrophil InfiltrationOralOrthologous GeneOspC proteinPathogenesisPeptide HydrolasesPersonsPreventionProcessProteinsRegulationResearchRoleShigellaShigella InfectionsSpecificitySwellingTestingTissuesType III Secretion System PathwayUbiquitinVariantWorkcell motilitycytokinedesignenteric infectionenteric pathogengain of functionguanylategut inflammationhuman pathogenimprovedinnovationinterestintestinal epitheliumneutrophilnovelpathogenpathogenic bacteriarecruitsensor
项目摘要
Shigella species are important, highly infectious pathogens of humans. In 2016, there were ~269 million cases
and 212,000 deaths due to Shigella. Infection with Shigella is associated with inflammation due to the recruitment
of neutrophils to the colon and massive tissue destruction. Despite this impressive host response, Shigella
survive in this harsh environment, primarily by replicating within and spreading between colonic epithelial cells
(ECs). Shigella survive by directly usurping and reprogramming host cell processes through the activity of ~30
type III effectors, proteins that they directly inject into the host cell cytosol via a highly conserved type III secretion
system (T3SS). Our research's overall goal is to use Shigella as a model pathogen to decipher the mechanisms
that enable intracellular pathogens to evade host innate immune responses and establish a replicative niche with
the cytosol of intestinal ECs. We have a long-standing interest in identifying and deciphering roles for effectors
in specific steps in Shigella pathogenesis. The first line of defense that Shigella and other enteric pathogens face
upon trying to establish a replicative niche within the gastrointestinal tract is the induction of the death of intestinal
ECs via pyroptosis. Pyroptosis is an inflammatory form of cell death that, if not inhibited, results in the rapid lysis
and/or expulsion of infected ECs from the intestinal epithelium and the processing and release of pro-
inflammatory cytokines. Here, we propose to investigate how Shigella type III secreted effectors cooperate to
inhibit pyroptosis, thus enabling this professional intracytoplasmic pathogen to establish a replicative niche within
the cytosol of intestinal epithelial cells. These studies are designed to significantly expand our understanding of
how Shigella, and likely other enteric pathogens, inhibit inflammasomes. At the completion of the proposed aims,
it is expected that the knowledge gained can be applied towards the development of novel host-based
interventions for the prevention and treatment of enteric infections, a particularly pressing need given emerging
issues with antibiotic resistance.
志贺氏菌属是人类重要的高传染性病原体。2016年,约有2.69亿例
21.2万人死于志贺氏菌志贺氏菌感染与炎症有关,
嗜中性粒细胞扩散到结肠并造成大量组织破坏尽管宿主的反应令人印象深刻,
在这种恶劣的环境中生存,主要是通过在结肠上皮细胞内复制和在结肠上皮细胞之间传播
(EC)。志贺氏菌通过~30的活性直接篡夺和重编程宿主细胞过程而存活
III型效应物,它们通过高度保守的III型分泌直接注入宿主细胞胞质溶胶的蛋白质
系统(T3 SS)。我们的研究的总体目标是使用志贺氏菌作为模式病原体来破译机制
使细胞内病原体能够逃避宿主的先天免疫反应,并建立一个复制生态位,
肠内皮细胞的胞质溶胶。我们有一个长期的兴趣在识别和破译的作用效应
志贺氏菌致病的特定步骤。志贺氏菌和其他肠道病原体面临的第一道防线
当试图在胃肠道内建立一个复制生态位时,
通过焦亡引起的内皮细胞损伤细胞凋亡是一种炎症性细胞死亡,如果不加以抑制,
和/或受感染的EC从肠上皮中排出,以及前-
炎性细胞因子在这里,我们建议调查如何志贺氏菌III型分泌的效应合作,
抑制焦亡,从而使这种专业的胞质内病原体建立一个复制生态位内
肠上皮细胞的细胞质。这些研究旨在显著扩大我们对
志贺氏菌和其他可能的肠道病原体如何抑制炎性小体。在完成拟议目标时,
预计所获得的知识可以应用于新型基于主机的开发
预防和治疗肠道感染的干预措施,这是一个特别迫切的需要,
抗生素耐药性的问题。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CAMMIE LESSER其他文献
CAMMIE LESSER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CAMMIE LESSER', 18)}}的其他基金
Designer EcN for treatment of solid tumors
用于治疗实体瘤的 Designer EcN
- 批准号:
10459848 - 财政年份:2022
- 资助金额:
$ 76.16万 - 项目类别:
Designer EcN for treatment of solid tumors
用于治疗实体瘤的 Designer EcN
- 批准号:
10565935 - 财政年份:2022
- 资助金额:
$ 76.16万 - 项目类别:
Dissecting the means by which type 3 substrates are defined & secreted
剖析 3 类底物的定义方式
- 批准号:
10328544 - 财政年份:2019
- 资助金额:
$ 76.16万 - 项目类别:
Dissecting the means by which type 3 substrates are defined & secreted
剖析 3 类底物的定义方式
- 批准号:
10274790 - 财政年份:2019
- 资助金额:
$ 76.16万 - 项目类别:
Dissecting the means by which type 3 substrates are defined & secreted
剖析 3 类底物的定义方式
- 批准号:
10411510 - 财政年份:2019
- 资助金额:
$ 76.16万 - 项目类别:
Dissecting the means by which type 3 substrates are defined & secreted
剖析 3 类底物的定义方式
- 批准号:
10553659 - 财政年份:2019
- 资助金额:
$ 76.16万 - 项目类别:
Dissecting the means by which type 3 substrates are defined & secreted
剖析 3 类底物的定义方式
- 批准号:
10589974 - 财政年份:2019
- 资助金额:
$ 76.16万 - 项目类别:
PIPs: a new means to identify effector-target interactions
PIP:识别效应器-目标相互作用的新方法
- 批准号:
8777643 - 财政年份:2014
- 资助金额:
$ 76.16万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 76.16万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 76.16万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 76.16万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 76.16万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 76.16万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 76.16万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 76.16万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 76.16万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 76.16万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 76.16万 - 项目类别:
Operating Grants